CoChat

Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis

Open access
Duckworth, Carrie A., Guimond, Scott E., Sindrewicz, Paulina, Hughes, Ashley J., French, Neil S., Lian, Lu-Yun, Yates, Edwin A., Pritchard, D. Mark, Rhodes, Jonathan M., Turnbull, Jeremy E., Yu, Lu-Gang · 2015 · Oncotarget
Cited by 53

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

// Carrie A. Duckworth 1, * , Scott E. Guimond 2, * , Paulina Sindrewicz 1 , Ashley J. Hughes 2, 4 , Neil S. French 3 , Lu-Yun Lian 2 , Edwin A. Yates 2 , D. Mark Pritchard 1 , Jonathan M. Rhodes 1 , Jeremy E. Turnbull 2 , Lu-Gang Yu 1 1 Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 2 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom 3 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 4 Diamond Light Source Ltd, Harwell Innovation Campus, Didcot, United Kingdom * These authors have contributed equally to this work Correspondence to: Lu-Gang Yu, e-mail: lgyu@liv.ac.uk Jeremy E. Turnbull, e-mail: j.turnbull@liv.ac.uk Keywords: galectin-3, metastasis, heparin Received: September 29, 2014 Accepted: June 12, 2015 Published: June 23, 2015 ABSTRACT Concentrations of circulating galectin-3, a metastasis promoter, are greatly increased in cancer patients. Here we show that 2- or 6-de- O -sulfated, N -acetylated heparin derivatives are galectin-3 binding inhibitors. These chemically modified heparin derivatives inhibited galectin-3-ligand binding and abolished galectin-3-mediated cancer cell-endothelial adhesion and angiogenesis. Unlike standard heparin, these modified heparin derivatives and their ultra-low molecular weight sub-fractions had neither anticoagulant activity nor effects on E-, L- or P-selectin binding to their ligands nor detectable cytotoxicity. Intravenous injection of such heparin derivatives (with cancer cells pre-treated with galectin-3 followed by 3 subcutaneous injections of the derivatives) abolished the circulating galectin-3-mediated increase in lung metastasis of human melanoma and colon cancer cells in nude mice. Structural analysis using nuclear magnetic resonance and synchrotron radiation circular dichroism spectroscopies showed that the modified heparin derivatives bind to the galectin-3 carbohydrate-recognition domain. Thus, these chemically modified, non-anticoagulant, low-sulfated heparin derivatives are potent galectin-3 binding inhibitors with substantial potential as anti-metastasis/cancer drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4409

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 53

Metadata

Authors
Duckworth, C. A., Guimond, S. E., Sindrewicz, P., Hughes, A. J., French, N. S., Lian, L.-Y., Yates, E. A., Pritchard, D. M., Rhodes, J. M., Turnbull, J. E., & Yu, L.-G.
Venue
Oncotarget
Published
2015-06-23
Volume
6
Issue
27
Pages
23671-23687
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2130812849
Cited by
53
References
1
FWCI
2.06
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.